Why the study?
Although hospital-at-home programs showed initial benefits for older individuals, the robustness and magnitude of these effects relative to conventional hospital care required validation through a comprehensive meta-analysis.
Does early discharge Hospital-at-Home reduce mortality, readmission, and treatment duration in older adults compared to routine hospital care?
Does early discharge Hospital-at-Home reduce mortality, readmission, and treatment duration in older adults compared to routine hospital care?
Early discharge Hospital-at-Home programs for older adults may reduce mortality and treatment duration, but their impact on readmission and functional status remains inconclusive.
Use early-discharge HaH cautiously in older adults given possible functional decline; leaves open mortality benefit confirmation in RCTs.
Background The global population of adults aged 60 and above surpassed 1 billion in 2020, constituting 13.5% of the global populace. Projections indicate a rise to 2.1 billion by 2050. While Hospital-at-Home (HaH) programs have emerged as a promising alternative to traditional routine hospital care, showing initial benefits in metrics such as lower mortality rates, reduced readmission rates, shorter treatment durations, and improved mental and functional status among older individuals, the robustness and magnitude of these effects relative to conventional hospital settings call for further validation through a comprehensive meta-analysis. Methods A comprehensive literature search was executed during April–June 2023, across PubMed, MEDLINE, Embase, Web of Science, and Cumulative Index of Nursing and Allied Health Literature (CINAHL) to include both RCT and non-RCT HaH studies. Statistical analyses were conducted using Review Manager (version 5.4), with Forest plots and I 2 statistics employed to detect inter-study heterogeneity. For I 2 > 50%, indicative of substantial heterogeneity among the included studies, we employed the random-effects model to account for the variability. For I 2 ≤ 50%, we used the fixed effects model. Subgroup analyses were conducted in patients with different health conditions, including cancer, acute medical conditions, chronic medical conditions, orthopedic issues, and medically complex conditions. Results Fifteen trials were included in this systematic review, including 7 RCTs and 8 non-RCTs. Outcome measures include mortality, readmission rates, treatment duration, functional status (measured by the Barthel index), and mental status (measured by MMSE). Results suggest that early discharge HaH is linked to decreased mortality, albeit supported by low-certainty evidence across 13 studies. It also shortens the length of treatment, corroborated by seven trials. However, its impact on readmission rates and mental status remains inconclusive, supported by nine and two trials respectively. Functional status, gauged by the Barthel index, indicated potential decline with early discharge HaH, according to four trials. Subgroup analyses reveal similar trends. Conclusions While early discharge HaH shows promise in specific metrics like mortality and treatment duration, its utility is ambiguous in the contexts of readmission, mental status, and functional status, necessitating cautious interpretation of findings.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: